BioCentury

@BioCentury

The leading voice for decision makers throughout the global healthcare ecosystem.

Vrijeme pridruživanja: prosinac 2010.

Tweetovi

Blokirali ste korisnika/cu @BioCentury

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioCentury

  1. prije 10 sati

    GSK to provide adjuvant to boost effectiveness and stretch supplies of vaccines

    Poništi
  2. proslijedio/la je Tweet
    1. velj

    Well that’s a wrap on Europe for the UK (😞). But UK biotech still wants to tango. We‘ve got the companies, you’ve got the regulators- let’s dance. with the story, in .

    Poništi
  3. 1. velj

    It's been a bad year for abuse-deterrent opioids. Here's what that means for the drug class, and how the path forward might look.

    Poništi
  4. 1. velj

    A study from NCI's Steve Rosenberg suggests the solid tumor-fighting powers of TILs could also be sourced from blood.

    Poništi
  5. 1. velj

    ., , demonstrate how a cell-based fluorescence assay can be used in drug discovery to predict the potency of compounds that allosterically modulate transcription factor dimerization

    Poništi
  6. 1. velj

    An overview from on how is deciding which technologies to apply to different cancer settings

    Poništi
  7. 1. velj

    EMA's CHMP recommended a basket of therapies including Alnylam's RNAi therapeutic Givlaari, Novo's oral diabetes treatment Rybelsus, Esperion's bempedoic acid alone and in combination, and more ;

    Poništi
  8. 1. velj

    Reata had double-digit gains Friday after Amgen revealed interest in renal opportunities on earnings call. The pharma itself dipped due to lower-than-expected FY20 guidance

    Poništi
  9. 1. velj

    Cardior's preclinical POC data for its first clinical candidate shows the miR-132 inhibitor goes beyond treating the cardiovascular symptoms of to reverse established disease in animal models

    Poništi
  10. 1. velj

    BioCentury's preclinical roundup includes CEPI funding for CureVac on 2019-nCoV ; plus blockade of CD47-SIRPA for atherosclerosis, Stanford and IBM-CDHI

    Poništi
  11. 1. velj

    Wuhan, the epicenter of the outbreak, is home to a large chunk of China's clinical trials.

    Poništi
  12. 1. velj

    BioCentury's latest roundup of management moves includes a trio of women appointed to C-suite positions; plus an FDA director retires, and more

    Poništi
  13. 1. velj

    Dermatology company Arcutis made its public debut, raising $159 million. The biotech is the third to close a NASDAQ IPO this year

    Poništi
  14. 1. velj

    FDA continues its run of indication-first approvals with Aimmune’s peanut allergy therapy Palforzia

    Poništi
  15. 1. velj

    What Exscientia and Sumitomo Dainippon's trial launch does and doesn't say about AI's potential in drug development.

    Poništi
  16. proslijedio/la je Tweet
    25. sij

    Want to know who’s doing what to get CAR Ts to solid tumors? Winnie Pong has sliced and diced the data in . Take-home message: the majority are going after non-validated targets. Less of the lemming factor than in other areas of IO.

    Poništi
  17. 31. sij

    U.S. declares #2019-nCoV public health emergency. Separate declarations will be needed if FDA is going to issue Emergency Use Authorizations for use of unapproved diagnostics, drugs or vaccines.

    Poništi
  18. 31. sij

    With complete, the British biotech sector is focused on close regulatory cooperation with EMA and access to global talent as top priorities for coming trade negotations, Steve Bates tells

    Poništi
  19. 31. sij

    CSL's logistics capabilities could give it a leg up as the company expands into cell and gene therapy

    Poništi
  20. 31. sij

    BioCentury's latest roundup of biotech financial news: Winning hand for Black Diamond in NASDAQ debut; Trikafta sales bolster Vertex; Alexion slips on guidance and more

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·